Valuation: Insulet Corporation

Market Cap 10.38B 9.27B 8.5B 7.74B 14.5B 983B 14.79B 102B 40.95B 519B 38.96B 38.13B 1,638B P/E 2026 *
24.6x
P/E 2027 * 19.6x
Enterprise Value 10.43B 9.31B 8.55B 7.77B 14.57B 987B 14.86B 102B 41.14B 521B 39.15B 38.31B 1,646B EV / Sales 2026 *
3.17x
EV / Sales 2027 * 2.69x
Free-Float
97.63%
Yield 2026 *
-
Yield 2027 * -
1 day+2.52%
1 week+2.38%
Current month+2.09%
1 month+16.04%
3 months-9.95%
6 months-10.84%
Current year-46.24%
1 week 146.62
Extreme 146.62
154.95
1 month 131.22
Extreme 131.225
154.95
Current year 126.4
Extreme 126.4
299.8
1 year 126.4
Extreme 126.4
354.88
3 years 126.4
Extreme 126.4
354.88
5 years 125.82
Extreme 125.82
354.88
10 years 30.69
Extreme 30.69
354.88
Manager TitleAgeSince
Chief Executive Officer 55 28/04/2025
Director of Finance/CFO 53 30/09/2025
Compliance Officer 50 01/12/2022
Director TitleAgeSince
Director/Board Member 61 27/07/2015
Director/Board Member 54 20/10/2020
Director/Board Member 55 18/10/2021
Date Insider Type Main position Quantity % Market Cap. Importance
1/10/26 Tax

Chief Financial Officer

-1,882 0.0027%
30/9/26 Free

Director

141 0.0002%
30/9/26 Free

Director

178 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
+2.53%+2.38%-52.06%+8.81% 10.38B
+3.59%+4.99%-11.09%+14.75% 184B
+2.34%+4.30%+9.61%+37.15% 118B
+4.89%-0.12%-14.63%+9.89% 111B
+1.41%+6.80%-41.04%+6.45% 94.58B
+1.40%+1.54%-1.72%+74.35% 63.13B
-5.48%-5.08%-1.24%+63.86% 55.66B
+0.84%+1.47%+12.40%-22.13% 53.9B
+20.61%+16.33%-8.25%+58.14% 43.42B
+2.23%+4.24%+2.48%-8.32% 34.68B
Average +3.42%+0.10%-10.55%+24.29% 76.88B
Weighted average by Cap. +3.15%+0.24%-8.75%+23.66%

Financials

2026 *2027 *
Net sales 3.29B 2.93B 2.69B 2.45B 4.59B 311B 4.68B 32.16B 12.96B 164B 12.34B 12.07B 519B 3.73B 3.33B 3.06B 2.78B 5.22B 353B 5.32B 36.53B 14.72B 187B 14.01B 13.71B 589B
Net income 425M 380M 348M 317M 594M 40.25B 606M 4.16B 1.68B 21.25B 1.6B 1.56B 67.11B 534M 477M 437M 398M 746M 50.54B 761M 5.22B 2.11B 26.68B 2B 1.96B 84.26B
Net Debt 49.62M 44.3M 40.65M 36.98M 69.34M 4.7B 70.72M 486M 196M 2.48B 186M 182M 7.83B -322M -288M -264M -240M -450M -30.52B -459M -3.15B -1.27B -16.11B -1.21B -1.18B -50.88B
Projected Income Statement - Annual - Insulet Corporation
Logo Insulet Corporation
Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows: - Insulin pump therapy systems (98.7%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand); - non-insulin drug administration systems (1.3%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy). At the end of 2025, the group had 2 production sites located in the United States and in China. The United States account for 72.2% of net sales.
Employees
5,400
Date Price Change Volume
03/11/26 USD 152.81 +2.09% 696,109
30/10/26 USD 149.68 -1.85% 1,090,208
29/10/26 USD 152.50 +2.40% 1,297,218
28/10/26 USD 148.93 -0.60% 1,035,225
27/10/26 USD 149.83 +0.38% 943,833
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - Insulet Corporation
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
149.68USD
Average target price
167.17USD
Spread / Average Target
+11.69%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Insulet Corporation
  1. Stock Market
  2. Stocks
  3. PODD Stock